Influenza C virus susceptibility to antivirals with different mechanisms of action.

Autor: Chesnokov A; Influenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA., Ivashchenko AA; ChemDiv, San Diego, California, USA., Matsuzaki Y; Department of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan., Takashita E; Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan., Mishin VP; Influenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA., Ivachtchenko AV; ChemDiv, San Diego, California, USA.; AVISA LLC, Hallandale Beach, Florida, USA., Gubareva LV; Influenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.
Jazyk: angličtina
Zdroj: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 May 02; Vol. 68 (5), pp. e0172723. Date of Electronic Publication: 2024 Apr 08.
DOI: 10.1128/aac.01727-23
Abstrakt: Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC 50 8-22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses.
Competing Interests: Andrei A. Ivashchenko and Alexandre V. Ivachtchenko are the cofounders of ChemDiv, managing members of AVISA LCC. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Databáze: MEDLINE
Externí odkaz: